{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-045456","form_type":"8-K","ticker":"LNTH","cik":"0001521036","company_name":"Lantheus Holdings, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.675581+00:00","generated_at":"2026-05-30T04:29:07.666139+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lantheus Q3 revenue up 18.4% to $378.7M; adjusted EPS $1.70 beats prior year","bullets":["GAAP net income $131.1M ($1.79 diluted EPS) vs $132.0M ($1.88) in Q3 2023.","PYLARIFY sales $259.8M (+20.6%); DEFINITY sales $77.0M (+14.3%).","Acquired NAV-4694, a Phase 3 beta-amyloid imaging agent; NDA planned for 2026.","CMS CY2025 final rule improves separate payment for diagnostic radiopharmaceuticals including PYLARIFY, effective Jan 1, 2025.","FY2024 guidance narrowed: revenue $1.51B-$1.52B; adj. EPS $6.65-$6.70, at higher end of prior range."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-045456","json":"https://secwatch.observer/filing/0001628280-24-045456.json","markdown":"https://secwatch.observer/filing/0001628280-24-045456.md","text":"https://secwatch.observer/filing/0001628280-24-045456.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521036/000162828024045456/0001628280-24-045456-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521036/000162828024045456/lnth-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:29:07.666139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}